Table 2.

Overview of compliance and TEAEs by treatment group

	Pooled placebo (N=5)	Mezagitamab 45 mg (N=6)	Mezagitamab 90 mg (N=6)	Mezagitamab 135 mg (N=5)
Treatment compliance (%)*
Mean (SD)	80.0 (20.9)	79.2 (18.8)	62.5 (34.5)	70.0 (20.9)
Median	75.0	75.0	62.5	75.0
Min, Max	50, 100	50, 100	25, 100	50, 100
TEAE
Any TEAE (% of patients)	3 (60.0)	4 (66.7)	6 (100.0)	2 (40.0)
Grade 3 or higher TEAE	0	0	0	0
Drug-related TEAE (% of patients)	1 (20.0)	1 (16.7)	1 (16.7)	1 (20.0)
Drug-related grade 3 or higher TEAE	0	0	0	0
Treatment-emergent SAEs (% of patients)	0	1 (16.7)	0	1 (20.0)
Drug-related treatment-emergent SAEs	0	0	0	0
TEAEs resulting in study drug dose modification† (% of patients)	0	1 (16.7)	0	1 (20.0)
TEAEs resulting in study drug discontinuation (% of patients)	0	0	0	1 (20.0)
Deaths	0	0	0	0

*Treatment compliance (%) was calculated as (actual number of doses taken)/(planned number of doses) × 100.

†Dose modification includes dose interrupted and drug withdrawn.

SAE, serious adverse event; TEAE, treatment-emergent adverse event.